在心脏和血管重塑中使用前列腺素
Emanuela Ricciotti1,2, Philip G Haines3, William Chai4
1Department of Systems Pharmacology and Translational Therapeutics (E.R., G.A.F.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
Arteriosclerosis, thrombosis, and vascular biology
|January 25, 2024
概括
非类固醇抗炎药物 (NSAIDs) 可能通过促进不良的心肌和血管重塑,增加心力衰竭风险. 针对特定的前列腺素可以抵消这些有害影响.
科学领域:
- 生物化学 生化学
- 心血管药理学心血管药理学
- 分子医学是分子医学.
背景情况:
- 通过循环氧化酶 (COX) 酶从酸中提取的前列腺素是关键的脂质媒介物.
- 非类固醇抗炎药物 (NSAIDs) 抑制COX活性,减少前列腺类生物合成,并产生抗炎,抗发烧和止痛作用.
- 使用NSAID与心血管风险有关,包括高血压和动脉血事件,主要是通过抑制血管保护性前列腺素.
研究的目的:
- 审查前列腺素在心肌和血管改造中的作用.
- 探索NSAID与心力衰竭风险之间的联系.
- 为了确定潜在的治疗策略,针对前列腺体,以抵消不适应性重塑.
主要方法:
- 对前列腺类药物,NSAIDs和心血管改造现有研究的文献综述.
- 对前列腺类药物影响心脏和血管结构和功能变化的机制的分析.
- 综合证据,将NSAID诱导的前列腺抑制与不利的重塑途径联系起来.
主要成果:
- 前列腺素在调节心肌和血管重塑中发挥着关键作用,以应对各种刺激.
- 无抗炎药可以通过减少前列腺体信号传递来促进有害的重塑过程,从而加剧心力衰竭的风险.
- 特定的前列腺都涉及到保护性和有害性重塑,这表明有针对性的干预可能性.
结论:
- NSAIDs对心力衰竭风险的影响部分是由它们对前列腺驱动的心肌和血管重塑的影响.
- 了解不同前列腺素在重塑中的特定作用对于开发更安全的抗炎疗法至关重要.
- 向特定的前列腺路提供了一种潜在的策略,以减轻NSAID相关的心血管风险,特别是心力衰竭.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
182
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
182
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:23Antihypertensive Drugs: Vasodilators
525
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
525
01:26Heart Failure Drugs: Inotropic Agents
588
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
01:22Heart Failure Drugs: β-Blockers
340
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
01:24Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K